Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 657-666

  Zhang, Yan Jin ^a,b   Patel, Deendayal ^a,c   Nan, Yuchen ^a   Fan, Sumin ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b Bldg 142   (United States)

^c HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; PEPTIDE CP1; PEPTIDE DERIVATIVE; PEPTIDE KP1; PEPTIDE KP2; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER DERIVATIVE; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; HERPES SIMPLEX; HUMAN HERPESVIRUS 8; INFECTION CONTROL; INTERFERON REGULATORY FACTOR 1 GENE; INTERLEUKIN 6 GENE; LYMPHOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERITONEUM LAVAGE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR ENGRAFTMENT; VIRUS GENE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; INTERFERON REGULATORY FACTORS; INTERLEUKIN-6; LYMPHOMA, PRIMARY EFFUSION; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; MORPHOLINOS; SARCOMA, KAPOSI; SEVERE COMBINED IMMUNODEFICIENCY; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION; VIRAL PROTEINS;

EID: 80052452377     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1810     Document Type: Article

References (40)

1. Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274:1739-1744. (Pubitemid 26414912)
2. Nicholas J., Ruvolo V.R., Burns W.H., et al. Kaposi's sarcomaassociated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 1997; 3:287-292. (Pubitemid 27112925)
3. Engels E.A., Pfeiffer R.M., Goedert J.J., et al. Trends in cancer risk among people with AIDS in the United States 1980- 2002. AIDS 2006; 20:1645-1654. (Pubitemid 44162407)
4. Robles R., Lugo D., Gee L., Jacobson M.A. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:34-38. (Pubitemid 29045467)
5. Little R.F., Merced-Galindez F., Staskus K., et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 2003; 187:149-153. (Pubitemid 36034485)
6. Summerton J. Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489:141-158.
7. Enterlein S., Warfield K.L., Swenson D.L., et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006; 50:984-993. (Pubitemid 43327804)
8. Warfield K.L., Swenson D.L., Olinger G.G., et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006; 2:e1.
9. Yuan J., Stein D.A., Lim T., et al. Inhibition of Coxsackievirus B3 in cell-cultures and in mice by peptide-conjugated morpholino oligomers targeting the IRES. J Virol 2006; 80:11510-11519. (Pubitemid 44788866)
10. Burrer R., Neuman B.W., Ting J.P., et al. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J Virol 2007; 81:5637-5648. (Pubitemid 46847003)
11. Stein D.A., Huang C.Y., Silengo S., et al. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother 2008; 62:555-565.
12. Deas T.S., Binduga-Gajewska I., Tilgner M., et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005; 79:4599-4609. (Pubitemid 40464211)
13. Deas T.S., Bennett C.J., Jones S.A., et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 2007; 51:2470-2482. (Pubitemid 47047326)
14. Russo J.J., Bohenzky R.A., Chien M.C., et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996; 93:14862-14867. (Pubitemid 26419060)
15. Renne R., Zhong W., Herndier B., et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996; 2:342-346. (Pubitemid 26080656)
16. Gao S.J., Boshoff C., Jayachandra S., et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997; 15:1979-1985. (Pubitemid 27480686)
17. Zimring J.C., Goodbourn S., Offermann M.K. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol 1998; 72:701-707. (Pubitemid 28048889)
18. Burýsek L., Yeow W.S., Lubyova B., et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 1999; 73:7334-7342. (Pubitemid 29383216)
19. Seo T., Park J., Lee D., Hwang S.G., Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001; 75:6193-6198. (Pubitemid 32553150)
20. Mamane Y., Heylbroeck C., Genin P., et al. Interferon regulatory factors: The next generation. Gene 1999; 237:1-14. (Pubitemid 29406192)
21. Seo T., Lee D., Shim Y.S., et al. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol 2002; 76:8797-8807. (Pubitemid 34864075)
22. Lin R., Genin P., Mamane Y., et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 2001; 20:800-811. (Pubitemid 32198173)
23. Shin Y.C., Nakamura H., Liang X., et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006; 80:2257-2266. (Pubitemid 43271532)
24. Parravicini C., Corbellino M., Paulli M., et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151:1517-1522. (Pubitemid 27527913)
25. Sun R., Lin S.F., Staskus K., et al. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 1999; 73:2232-2242. (Pubitemid 29098128)
26. Cannon J.S., Nicholas J., Orenstein J.M., et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis 1999; 180:824-828. (Pubitemid 29411370)
27. Staskus K.A., Sun R., Miller G., et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol 1999; 73:4181-4187. (Pubitemid 29189863)
28. Molden J., Chang Y., You Y., Moore P.S., Goldsmith M.A.A. Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL- 6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997; 272:19625-19631. (Pubitemid 27337768)
29. Osborne J., Moore P.S., Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 1999; 60:921-927. (Pubitemid 29518115)
30. Zhang Y.J., Bonaparte R.S., Patel D., Stein D.A., Iversen P.L. Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus. Mol Cancer Ther 2008; 7:712-720. (Pubitemid 351482154)
31. Wu W., Rochford R., Toomey L., Harrington W., Jr., Feuer G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res 2005; 29:545-555. (Pubitemid 40327243)
32. Boshoff C., Gao S.J., Healy L.E., et al. Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 1998; 91:1671-1679. (Pubitemid 28110332)
33. Zhang Y.J., Wang K.Y., Stein D.A., et al. Inhibition of replication and transcription activator and latencyassociated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res 2007; 73:12-23. (Pubitemid 46080474)
34. Chen J., Ueda K., Sakakibara S., Okuno T., Yamanishi K. Transcriptional regulation of the Kaposi's sarcomaassociated herpesvirus viral interferon regulatory factor gene. J Virol 2000; 74:8623-8634. (Pubitemid 30666713)
35. Li M., Lee H., Guo J., et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol 1998; 72:5433-5440. (Pubitemid 28283324)
36. Zhang Y.J., Wang X.P., Deng J.H., et al. Suppression of oncogenic viral interferon regulatory factor (vIRF) of Kaposi's sarcoma-associated herpesvirus by ribozymemediated cleavage. Cancer Gene Ther 2001; 8:285-293.
37. Kedes D.H., Ganem D. Sensitivity of Kaposi's sarcomaassociated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082-2086. (Pubitemid 27203763)
38. Medveczky M.M., Horvath E., Lund T., Medveczky P.G. In vitro antiviral drug sensitivity of the Kaposi's sarcomaassociated herpesvirus. AIDS 1997; 11:1327-1332. (Pubitemid 27423292)
39. Sergerie Y., Boivin G. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J Clin Microbiol 2003; 41:3897-3900. (Pubitemid 36994736)
40. Curreli F., Cerimele F., Muralidhar S., et al. Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. J Virol 2002; 76:5208-5219. (Pubitemid 34441724)